Beyond Hormone Receptor Positivity: Prognostic Value of ER, PR, and Ki-67 Expression Levels in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: A Multicenter Real-World Study

Background and Objectives: Clinical outcomes remain heterogeneous in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer receiving cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. We evaluated the prognostic relevance and incremental prognostic value of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression beyond clinical and treatment-related factors. Materials and Methods: This multicenter retrospective study included 568 patients treated with ribociclib- or palbociclib-based therapy between 2019 and 2024. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier and Cox regression analyses. The incremental prognostic value of ER, PR, and Ki-67 was assessed using nested Cox models with identical baseline clinical covariates and patient samples. Additional spline and exploratory cut-off analyses were performed. Results: Median PFS and OS were 29.23 and 44.43 months, respectively. Liver metastasis was independently associated with shorter PFS (HR 1.77, 95% CI 1.27–2.48; p = 0.001) and OS (HR 1.80, 95% CI 1.24–2.61; p = 0.002). Lung metastasis and prior endocrine therapy were independently associated with shorter PFS, whereas older age and prior endocrine therapy were associated with shorter OS. Although higher PR and lower Ki-67 expression were associated with longer PFS in univariable analyses, higher Ki-67 expression was independently associated with shorter PFS in the multivariable model (HR 1.008, p = 0.025), whereas ER and PR were not significantly associated with PFS or OS. Adding ER, PR, and Ki-67 to baseline clinical models did not significantly improve model fit for PFS (p = 0.087) or OS (p = 0.320). No significant nonlinear associations were identified, and exploratory cut-offs demonstrated limited stability. Exploratory subgroup analyses suggested incremental prognostic value in first-line treatment (p = 0.003), although the treatment-line interaction was not significant. Conclusions: Ki-67 showed an independent association with PFS, although the combined incremental prognostic value of ER, PR, and Ki-67 beyond clinical factors was limited. Further prospective studies are warranted to clarify their clinical utility.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-19
DOI
https://doi.org/10.3390/medicina62112275
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Beyond Hormone Receptor Positivity: Prognostic Value of ER, PR, and Ki-67 Expression Levels in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: A Multicenter Real-World Study

Ece Ulukal Karancı, Derya Kıvrak Salim, Esma Uguztemur, Ahmet Fatih Oruç et al.
Medicina
Advanced Breast Cancer Therapies
article

Beyond Hormone Receptor Positivity: Prognostic Value of ER, PR, and Ki-67 Expression Levels in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: A Multicenter Real-World Study

Ece Ulukal Karancı, Derya Kıvrak Salim, Esma Uguztemur, Ahmet Fatih Oruç, Atila Yıldırım, Seval Akay, Seval Ay, Ahmet Kürşad Dişli, Şafak Yıldırım Dişli, Banu Öztürk, Esra Aşık, Melek Eryilmaz Karakurt
article en

Abstract

Background and Objectives: Clinical outcomes remain heterogeneous in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer receiving cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. We evaluated the prognostic relevance and incremental prognostic value of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression beyond clinical and treatment-related factors. Materials and Methods: This multicenter retrospective study included 568 patients treated with ribociclib- or palbociclib-based therapy between 2019 and 2024. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier and Cox regression analyses. The incremental prognostic value of ER, PR, and Ki-67 was assessed using nested Cox models with identical baseline clinical covariates and patient samples. Additional spline and exploratory cut-off analyses were performed. Results: Median PFS and OS were 29.23 and 44.43 months, respectively. Liver metastasis was independently associated with shorter PFS (HR 1.77, 95% CI 1.27–2.48; p = 0.001) and OS (HR 1.80, 95% CI 1.24–2.61; p = 0.002). Lung metastasis and prior endocrine therapy were independently associated with shorter PFS, whereas older age and prior endocrine therapy were associated with shorter OS. Although higher PR and lower Ki-67 expression were associated with longer PFS in univariable analyses, higher Ki-67 expression was independently associated with shorter PFS in the multivariable model (HR 1.008, p = 0.025), whereas ER and PR were not significantly associated with PFS or OS. Adding ER, PR, and Ki-67 to baseline clinical models did not significantly improve model fit for PFS (p = 0.087) or OS (p = 0.320). No significant nonlinear associations were identified, and exploratory cut-offs demonstrated limited stability. Exploratory subgroup analyses suggested incremental prognostic value in first-line treatment (p = 0.003), although the treatment-line interaction was not significant. Conclusions: Ki-67 showed an independent association with PFS, although the combined incremental prognostic value of ER, PR, and Ki-67 beyond clinical factors was limited. Further prospective studies are warranted to clarify their clinical utility.

MedicinaVol. 62(11)
Karadeniz Technical University (TR), Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR), Necmettin Erbakan University (TR), Antalya Eğitim ve Araştırma Hastanesi (TR), İzmir Şehir Hastanesi (TR), Antalya Şehi̇r Hastanesi̇ (TR), Kirsehir Training and Research Hospital (TR), Adıyaman Eğitim ve Araştırma Hastanesi (TR)
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon